Navigation Links
HMS Holdings Corp. Announces Q2 2009 Results and Raises 2009 Guidance
Date:7/31/2009

xes, depreciation and amortization, and share-based compensation expense (adjusted EBITDA) was $16.4 million for the second quarter of 2009, an increase of 32.7% over the same period a year ago. Reconciliation of net income to Three Months Six months EBITDA and adjusted EBITDA Ended Ended June 30, June 30, 2009 2008 2009 2008 ---- ---- ---- ---- Net Income $6,638 $5,001 $12,343 $8,174 Net interest (income) expense 222 219 412 437 Income taxes 4,580 3,622 8,545 5,920 Depreciation and amortization, net of deferred financing costs, included in net interest expense (income) 3,364 2,809 6,678 5,669 ----- ----- ----- ----- Earnings before interest, taxes, depreciation and amortization (EBITDA) 14,804 11,651 27,978 20,200 Share-based compensation expense 1,612 721 2,920 1,518 ----- --- ----- ----- Adjusted EBITDA $16,416 $12,372 $30,898 $21,718 ======= ======= ======= =======


'/>"/>
SOURCE HMS Holdings Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Zimmer Holdings to Present at BMO Capital Markets Ninth Annual Focus on Healthcare Conference
2. China Pharma Holdings, Inc. to Report Second Quarter 2009 Financial Results on August 12, 2009
3. American CareSource Holdings Increases ACS Networks Convenience and Quality With MinuteClinic Signing
4. Duane Reade Holdings, Inc. to Report Second Quarter 2009 Financial Results
5. SETO Holdings, Inc. Enters Into Two Additional Leases for Two New Hearing Centers in Maryland and Virginia
6. Duane Reade Holdings, Inc. Amends Terms and Extends Deadlines for Previously Announced Cash Tender Offers for Senior Secured Floating Rate Notes and Senior Subordinated Notes
7. Eastern Insurance Holdings, Inc. to Release 2nd Quarter 2009 Financial Results
8. Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2009 Third Quarter Earnings Webcast
9. Connectyx Technologies Holdings Group, Inc. to Begin Process to Become Fully Reporting and Up List to a Higher Exchange - As Stated on Wallstreetcorner.com
10. Zimmer Holdings, Inc. Reports Second Quarter 2009 Financial Results
11. JAG Media Holdings, Inc. Announces a Further Update of the Status of Its Acquisition of CardioGenics Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Patriot Scientific Corporation Announces New Director 2Health News:Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards 2Health News:Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards 3Health News:Washington Regional Partners with U.S. Preventive Medicine to Bring a New Level of Preventive Health Care Services to Northwest Arkansas 2Health News:Washington Regional Partners with U.S. Preventive Medicine to Bring a New Level of Preventive Health Care Services to Northwest Arkansas 3Health News:Lilly Announces the First 300-unit Vial of Insulin 2Health News:Lilly Announces the First 300-unit Vial of Insulin 3Health News:Lilly Announces the First 300-unit Vial of Insulin 4Health News:Industry Coalition Reissues Advisory Against Use of Dietary Supplements as Swine Flu Remedy, Cure 2Health News:Industry Coalition Reissues Advisory Against Use of Dietary Supplements as Swine Flu Remedy, Cure 3
Other Medicine News:Health News:Child mental health experts issue psychiatric medication treatment guidelines for preschoolers 2Health News:Child mental health experts issue psychiatric medication treatment guidelines for preschoolers 3Health News:Aerosol launches immune response in lungs to wipe out lethal infections 2Health News:Aerosol launches immune response in lungs to wipe out lethal infections 3Health News:Lymphatic vessel and lymph node function are restored with growth factor treatment 2Health News:Lymphatic vessel and lymph node function are restored with growth factor treatment 3Health News:Rosetta Genomics Strengthens Senior Management in Preparation for its First Commercial Launch of microRNA-Based Diagnostic Products in 2008 2Health News:Rosetta Genomics Strengthens Senior Management in Preparation for its First Commercial Launch of microRNA-Based Diagnostic Products in 2008 3Health News:Rosetta Genomics Strengthens Senior Management in Preparation for its First Commercial Launch of microRNA-Based Diagnostic Products in 2008 4Health News:Alfacell to Host Fiscal First Quarter 2008 Financial Results Conference Call and Webcast 2Health News:Superior Dental Care Alliance Launches Maximum Advantage Program 2
Breaking Medicine Technology:ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 2ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 3ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 5ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 6ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 7Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 1Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 2Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 3Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 4Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 5Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts 57353 1Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts 57353 2Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts 57353 3Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts 57353 4Experts to Highlight Key Trends in Physician and Healthcare Executive Recruitment Leadership and Compensation 57349 1Experts to Highlight Key Trends in Physician and Healthcare Executive Recruitment Leadership and Compensation 57349 2Experts to Highlight Key Trends in Physician and Healthcare Executive Recruitment Leadership and Compensation 57349 3